Bayesian and ML Emax model fitting, graphics and simulation for clinical dose
    response.  The summary data from the dose response meta-analyses in  
    Thomas, Sweeney, and Somayaji (2014) <doi:10.1080/19466315.2014.924876> and
    Thomas and Roy (2016) <doi:10.1080/19466315.2016.1256229> 
    Wu, Banerjee, Jin, Menon, Martin, and Heatherington(2017) <doi:10.1177/0962280216684528> 
    are included 
    in the package.  The prior distributions for the Bayesian analyses default to
    the posterior predictive distributions derived from these references.

Utilities to make your clinical collaborations easier if not
          fun. It contains functions for designing studies such as Simon
          2-stage and group sequential designs and for data analysis such
          as Jonckheere-Terpstra test and estimating survival quantiles.

A clinical significance analysis can be used to determine if an 
    intervention has a meaningful or practical effect for patients. You provide 
    a tidy data set plus a few more metrics and this package will take care of 
    it to make your results publication ready.

Provides estimates of several summary measures for clinical trials including
    the average hazard ratio, the weighted average hazard ratio, the restricted 
    superiority probability ratio, the restricted mean survival difference and 
    the ratio of restricted mean times lost, based on the short-term and 
    long-term hazard ratio model (Yang, 2005 <doi:10.1093/biomet/92.1.1>) 
    which accommodates various non-proportional hazards scenarios. The inference
    procedures and the asymptotic results for the summary measures are discussed 
    in Yang (2018, <doi:10.1002/sim.7676>).

Recalibrate risk scores (predicting binary outcomes) to improve clinical utility of risk score using weighted logistic or constrained logistic recalibration methods. Additionally, produces plots to assess the potential for recalibration to improve the clinical utility of a risk model. Methods are described in detail in Mishra, A. (2019) "Methods for Risk Markers that Incorporate Clinical Utility" <http://hdl.handle.net/1773/44068>.